Risperidone metabolic treatment

Moreover, according to Fiddle et al. (2000), after six weeks treatment with risperidone, the decreases in frontal lobe metabolism were more extensive. In other words, the risperidone produced a progressive chemical lobotomy with suppression of frontal lobe function. 

Chapter 1 examined three risperidone studies that confirm the braindisabling principles of psychiatric treatment by demonstrating that the drug causes a metabolic suppression in the frontal and temporal lobes (deactivation) that occurs in both normal persons and patients diagnosed with schizophrenia, and that this disabling effect correlates with a reduction in the expression of symptoms, such as hallucinations and delusions, that require a fully functioning brain. As previously noted, if measured, the effect would also correlate with an overall reduction in spontaneous mental activity and verbal expressions, which are common clinical phenomena in patients who experience psychomotor retardation in response to neuroleptics. 

These results suggest that in some individuals CYP3A4 plays a significant role in the metabolism of clozapine and that the combination of nefazodone and clozapine should therefore be used with caution. It is possible that in this case concomitant treatment with risperidone may have increased the effect of nefazodone to reduce the clearance of clozapine. 

The effects of neuroleptic drugs on serum lipids in adults have been reviewed (439). Haloperidol and the atypical neuroleptic drugs ziprasidone, risperidone, and aripipra-zole, are associated with lower risks of hyperlipidemia, whereas chlorpromazine, thioridazine, and the atypical drugs quetiapine, olanzapine, and clozapine are associated with higher risks. Treatment of the metabolic disturbances caused by neuroleptic drugs has also been reviewed (440). 

Another study in 24 schizophrenic patients investigated the effect of adding mirtazapine 30 mg at bedtime, for 6 weeks, to treatment with clozapine (9 patients), risperidone (8), or olanzapine (7). Mirtazapine had a negligible effect on the metabolism of all three drugs and the combination was well tolerated. ... 

De Hert M, Mittoux A, He Y, Peuskens J. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci 2011 261 231-9. 

Susceptibility factors A study of tumour necrosis factor-alpha (TNF-a) in 99 patients with bipolar depression found that treatment with olanzapine, quetiapine, risperidone, paliperidone or clozapine was associated with significantly greater TNF-a and a higher likelihood of metabolic syndrome [74FI TNF-a was greater in those with metabolic syndrome and there was a significant effect on the indirect relationship between antipsychotic treatment and elevated waist circumference. 

---